First-line (1L) treatment of follicular lymphoma (FL) with atezolizumab and obinutuzumab (A plus O) plus /- radiotherapy (RT): Results from the FLUORO study

被引：0
|
作者：
Chong, Geoffrey
Lee, Denise
Lee, Sze Ting
Grobler, Anneke
Khor, Richard
Campbell, Belinda A.
Thachil, Thanuja
Manos, Kate
Martynchyk, Arina
Douglas, Genevieve
Keane, Colm
Palmer, Jodie
Hawkes, Eliza Anne
机构：
[1] Grampians Hlth, Ballarat, Vic, Australia
[2] Eastern Hlth, Box Hill, Vic, Australia
[3] Austin Hlth, Dept Mol Imaging & Therapy, Heidelberg, Vic, Australia
[4] Univ Melbourne, Melbourne, Vic, Australia
[5] Olivia Newton John Canc Res Inst, Melbourne, Australia
[6] La Trobe Univ, Melbourne, Vic, Australia
[7] Murdoch Childrens Res Inst, Parkville, Vic, Australia
[8] Austin Hlth, Austin, Australia
[9] Peter MacCallum Canc Ctr, Melbourne, Australia
[10] Grampians Hlth, Ballarat, Vic, Australia
[11] Flinders Med Ctr, Adelaide, SA, Australia
[12] Univ Queensland, Frazer Inst, Brisbane, Qld, Australia
[13] Olivia NewtonJohn Canc Wellness & Res Ctr, Heidelberg, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7070
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Durvalumab ± tremelimumab plus platinum-etoposide in first-line (1L) extensive-stage SCLC (ES-SCLC): Results from the phase 3 CASPIAN study
    Grohe, C.
    Paz-Ares, L. G.
    Dvorkin, M.
    Chen, Y.
    Hotta, K.
    Trukhin, D.
    Statsenko, G.
    Hochmair, M. J.
    Ozguroglu, M.
    Ji, J. H.
    Voitko, O.
    Poltoratskiy, A.
    Verderame, F.
    Havel, L.
    Bondarenko, I.
    Armstrong, J.
    Byrne, N.
    Jiang, H.
    Goldman, J. W.
    Reinmuth, N.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 149 - 149
  • [42] Phase II COLET study: Atezolizumab (A) plus cobimetinib (C) plus paclitaxel (P)/nab-paclitaxel (nP) as first-line (1L) treatment (tx) for patients (pts) with locally advanced or metastatic triple-negative breast cancer (mTNBC).
    Brufsky, Adam
    Kim, Sung-Bae
    Zvirbule, Zanete
    Dirix, Luc Yves
    Eniu, Alexandru E.
    Carabantes, Francisco
    Izarzugaza, Yann
    Mebis, Jeroen
    Sohn, Joohyuk
    Wongchenko, Matthew
    Chohan, Saibah
    Amin, Reena
    McNally, V. A.
    Miles, David
    Loi, Sherene
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [43] Efficacy of Tiragolumab plus Atezolizumab in PD-L1 IHC and TIGIT Subgroups in the Phase II CITYSCAPE Study in First-Line NSCLC
    Patil, N.
    Cho, B. C.
    Johnson, M.
    Caro, R. B.
    Spira, A.
    Chiu, C.
    Molden, N.
    Pham, T.
    Yang, X.
    Choi, Y.
    Zhang, Z.
    Hoang, T.
    Ballinger, M.
    Meng, R.
    Rodriguez-Abreu, D.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S635 - S636
  • [44] Efficacy and safety of obinutuzumab for the first-line treatment of follicular lymphoma: a subgroup analysis of Chinese patients enrolled in the phase III GALLIUM study
    Hong, Xiaonan
    Song, Yuqin
    Shi, Yuankai
    Zhang, Qingyuan
    Guo, Wei
    Wu, Gang
    Li, Junmin
    Feng, Jifeng
    Kinkolykh, Anastasiia
    Knapp, Andrea
    Lin, Tongyu
    CHINESE MEDICAL JOURNAL, 2022, 135 (04) : 433 - 440
  • [45] Efficacy and safety of obinutuzumab for the first-line treatment of follicular lymphoma: a subgroup analysis of Chinese patients enrolled in the phase III GALLIUM study
    Hong Xiaonan
    Song Yuqin
    Shi Yuankai
    Zhang Qingyuan
    Guo Wei
    Wu Gang
    Li Junmin
    Feng Jifeng
    Kinkolykh Anastasiia
    Knapp Andrea
    Lin Tongyu
    中华医学杂志英文版, 2022, 135 (04) : 433 - 440
  • [46] Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Final analysis results of the RATIONALE-305 study
    Xu, R-H.
    Oh, D-Y.
    Kato, K.
    Arkenau, H-T.
    Tabernero, J.
    Cruz-Correa, M.
    Zimina, A. V.
    Bai, Y.
    Shi, J.
    Lee, K-W.
    Hirano, H.
    Spigel, D. R.
    Wyrwicz, L. S.
    Pazo Cid, R. A.
    Li, L.
    Xu, Y.
    McHenry, M. B.
    Yang, S.
    Moehler, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S1526 - S1527
  • [47] Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Final analysis results of the RATIONALE-305 study
    Xu, R-H.
    Oh, D-Y.
    Kato, K.
    Arkenau, T.
    Tabernero, J.
    Cruz-Correa, M.
    Zimina, A.
    Bai, Y.
    Shi, J.
    Lee, K-W.
    Hirano, H.
    Spigel, D. R.
    Wyrwicz, L. S.
    Cid, R. A. Pazo
    Li, L.
    Xu, Y.
    McHenry, M. B.
    Yang, S.
    Moehler, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S1320 - S1321
  • [48] FOLFOXIRI plus bevacizumab (bev) plus atezolizumab (atezo) versus FOLFOXIRI plus bev as first-line treatment of unresectable metastatic colorectal cancer (mCRC) patients: Results of the phase II randomized AtezoTRIBE study by GONO
    Cremolini, C.
    Rossini, D.
    Antoniotti, C.
    Pietrantonio, F.
    Lonardi, S.
    Salvatore, L.
    Marmorino, F.
    Borelli, B.
    Ambrosini, M.
    Barsotti, G.
    Di Stefano, B.
    Masi, G.
    Boccaccino, A.
    Tamberi, S.
    Tamburini, E.
    Frassineti, L. G.
    Simionato, F.
    Fontanini, G.
    Boni, L.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S1294 - S1295
  • [49] Comparison of first-line treatment with bendamustine plus rituximab versus R-CHOP for patients with follicular lymphoma grade 3A: Results of a retrospective study from the Fondazione Italiana Linfomi
    Margiotta-Casaluci, Gloria
    Bigliardi, Sara
    Cocito, Federica
    Meli, Erika
    Petrucci, Luigi
    Nicolosi, Maura
    Annibali, Ombretta
    Boccomini, Carola
    Bozzoli, Valentina
    Castellino, Alessia
    Cattina, Federica
    Cenfra, Natalia
    Ciavarella, Sabino
    Kovalchuk, Sofya
    Rotondo, Francesco
    Fama, Angelo
    Olivieri, Jacopo
    Zaja, Francesco
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [50] COMPARISON OF FIRST-LINE TREATMENT WITH BENDAMUSTINE PLUS RITUXIMAB VERSUS R-CHOP FOR PATIENTS WITH FOLLICULAR LYMPHOMA GRADE 3A: RESULTS OF AN ITALIAN MULTICENTER, RETROSPECTIVE STUDY
    Margiotta-Casaluci, G.
    Bigliardi, S.
    Cocito, F.
    Meli, E.
    Petrucci, L.
    Nicolosi, M.
    Annibali, O.
    Boccomini, C.
    Bozzola, V.
    Castellino, A.
    Cattina, F.
    Cenfra, N.
    Ciavarella, S.
    Kovalchuk, S.
    Rotondo, F.
    Fama, A.
    Olivieri, J.
    Zaja, F.
    HAEMATOLOGICA, 2021, 106 (10) : 91 - 91
12345